Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Technology appraisal guidance
Reference number: TA445
Published:
Please note that the timelines for this MTA have been revised and we now anticipate that the appraisal will start in approximately mid December 2015. The deadline for submissions is expected in approximately mid April 2016.